Giant cell arteritis (GCA) is rarely associated with cancer. The association paraneoplastic vasculitis and tumors appears to be more frequent with hematologic cancers. The authors report the case of 83-years-old Caucasian man, diagnosed with prostatic adenocarcinoma who developed a paraneoplastic GCA responsive to corticosteroids associated with disease progression.

This is the first report using an anti-tumor drug called Pazopanib for a case of solitary fibrous tumor that occurred in the ear canal. Pazopanib will be useful for clinicians involved in this case in the future, we have reported the detailed progress and immunological analysis.

We report a 64-years old man with B-cell CLL infected by SARS-CoV-2 during his hospitalization for a spondylodiscitis. Because of his health conditions the duration of the antiviral therapy was restricted to one week where we observed a transient disappearance of CD19+/CD5+ B-lymphocytes in peripheral blood.

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) of the breast is rare. We report a 59-year-old female with remote history of ductal carcinoma in situ treated with radiation and tamoxifen, who was recently diagnosed with CLL/SLL of contralateral breast after a localized suspicious cluster of masses was detected on routine mammography.

Solid Pseudopapillary Tumors of the Pancreas (SPTPs) are rare tumors with non-specific presentation which makes them a difficult diagnostic challenge. In our case the morphologic features of the tumor cells were similar to the cells seen in neuroendocrine tumors. The final diagnosis was made based on the results of Immunohistochemistry which cleared up the doubts and made SPTP the definitive diagnosis.

Bacillus Calmette-Guérin (BCG) is commonly used in treating superficial urothelial carcinoma. Though rare, local and systemic disseminated BCG infections are important to recognize as they require prolonged antimicrobial therapy and surveillance. We present an unusual case of a parapharyngeal space mass as manifestation of disseminated BCG following urothelial carcinoma treatment.

Hematologic malignancies are becoming more prevalent, manifesting in various clinical scenarios. Chronic myelogenous leukemia (CML) is usually diagnosed on routine complete blood count as it is typically asymptomatic. However, it can cause multiple signs and symptoms. We present a patient with appendicitis revealing CML during his workup for abdominal pain.

An 18-year-old female presented with hypopigmentation, ulcerative skin changes and masses of both breasts for over a year. She was referred to the Uganda Cancer Institute (UCI) with suspected inflammatory breast cancer. Radiological findings and trucut biopsy were consistent with secondary CD3+ CD20- T-cell NHL of both breasts.

A man aged 60’s suffered nephrotic syndrome with IgM nephropathy seven years earlier. Four years later, immune-checkpoint inhibitors (ICPIs) were administered against metastasizing pulmonary adenocarcinoma. Sixty-two weeks after 21 ICPIs injections, the cancer vanished but nephrotic syndrome relapsed. Acute pancreatitis followed and usual interstitial pneumonia exacerbated, as late-onset immune-related adverse-events.

Nivolumab is used for patients with recurrent/metastatic head and neck cancer resistant to platinum. We report a 76-year-old man with squamous cell carcinoma of the tongue, who developed toxic epidermal necrolysis (TEN) after nivolumab treatment. TEN is a fatal disease, and early treatment of the adverse events are important.

Burkitt lymphoma is a rapidly progressive disease which requires imaging, biopsy, prompt diagnosis and early aggressive chemotherapeutic treatment. We discuss a 7-year-old girl presenting with a persistent and painful unilateral swelling of the jaw. Lymphomas typically manifest as poor defined osteolytic lesions radiographically, as is presented in this case.

Neurofibromatosis type 1 (NF1) is a benign peripheral nerve sheath tumor which primarily cause neurocutaneous manifestations. We presented a rare case of periportal neurofibromatosis with intrahepatic, retroperitoneal and pelvic involvement. The patient underwent US-guided biopsy and a diagnosis of intrahepatic neurofibromatosis was made.

Cancer is emerging as a major public health concern in India with the ongoing demographic and epidemiological transition. This paper uses a nationally representative household survey to look at the general prevalence and economic burden of cancer in India. The average out of pocket spending on inpatient care in private facilities is about three-times that of public facilities. These efforts should specialize in the ten cancers contributing the very best DALYs in India, including cancers of the stomach, lung, pharynx aside from nasopharynx, colon and rectum, leukemia, oesophageal, and brain, and Systema nervosum, additionally to breast, lip and oral cavity, and cervical cancer, which are currently the main target of screening and early detection programs. India's current burden of 10,00,000 incident cancers is that the results of an epidemiologic transition, improved cancer diagnostics, and improved cancer data capture. The increasing incidence of cancer in India with wide interstate variations offers useful insights and important lessons for developing countries in managing their increasing cancer burdens. Overall, the cancer epidemiology literature from India is thinly dispersed. More studies with robust designs representing all parts of the country are currently needed.

Background Primary effusion lymphoma (PEL) is a rare disease occurs mostly in immunosuppressed young males. Treatment consists of chemotherapy and prognosis is poor. Case presentation Our case described immunocompetent elderly woman with PEL who survive 30 months without chemotherapy. Conclusion Physicians should be aware of all clinical scenarios of PEL

Cancer patients, particularly those post-surgery, are prone to skin infection following immersion in flood waters. We reported secondary surgical site infection in a postoperative 80-year-old post-operation breast cancer patient affected by Typhoon Hagibis. Individualized responses based on individual and environmental risks are crucial to alleviate the damage of disasters.

Multifocal lesions with necrotic center and peripheral enhancement can be a diagnostic challenge. Magnetic resonance imaging with advanced sequences, such as perfusion, can be confusing, as some inflammatory lesions can show hyperperfusion, mimicking tumors. We present a case of neurotuberculosis with multifocal lesions which diagnosis was confirmed by brain biopsy.

Non-Hodgkin's lymphoma of the female genital system is extremely rare. It may be confused with cervix uteri malignancies when being diagnosed.

A 60-year-old man presented to our hospital with pericardial effusion. He died of respiratory failure 13 months later. Autopsy revealed right atrial angiosarcoma extending into the right lung. To the best of our knowledge, this is the first case report of a primary cardiac angiosarcoma that displayed direct lung invasion.

The development of nanobubble technology provides a good means for tumor diagnosis and treatment. In this review, the research and development progress of nanobubbles is discussed. On the one hand, they can be used as a good contrast agent for tumors and effectively visualize the shape of tumors. On the other hand, due to its good water solubility, high drug loading rate and stability, it is used for the delivery of anti-tumor drugs, mainly including oxygen nanobubbles, which can significantly improve the efficacy of chemotherapeutic drugs through precise administration and targeted reoxygenation in the hypoxic area of the tumor; there are also vapor nanobubbles, which are formed by external forces (such as heat or sound) to induce instantaneous stimulation of nanoparticles, destroy the structure and release drugs to achieve therapeutic effects. Nanobubbles can also be used in combination therapy with other drugs. It is expected that this review will provide new ideas for tumor applications based on nanobubble technology and promote the process of tumor treatment.

Previously, little is known about the relationship between the PIK3R1 mutation status and the resistance to HER2-targeted therapies. Herein, we report a HER2-positive breast cancer patient with PIK3R1EY451delinsD showed resistance to HER2-targeted therapy, and adding everolimus to the treatment of trastuzumab and carboplatin achieved better effect.

NTRK gene-fusions are rare but can occur in diverse cancers. The NTRK inhibitor larotrectinib is newly approved by the FDA. This paper reports the first case of a man with a NTRK-rearranged soft tissue sarcoma treated with larotrectinib in the neoadjuvant setting, in Belgium, to avoid limb amputation.

Temozolomide (TMZ) is a standard of care treatment for Glioblastoma Multiforme (GBM). We report a fatal outcome of a 55 years old female with GBM who developed persistent aplastic anemia (AA) while being treated with TMZ. This case highlights the possibility of a dose-independent and fatal AA secondary to TMZ.

Background: Pulmonary metastasis(PM) form hepatocellular carcinoma(HCC) is a major indicator of a poor prognosis after liver resection. The study aimed to probe into the influencing factors for PM following open liver resection(OLR) and laparoscopic liver resection(LLR) with HCC. Method: All patients who suffered from LLR and OLR for primary HCC, who developed pulmonary metastasis, as first extrahepatic metastasis, were retrospectively analyzed in our department from January 2014 to August 2020. Results: Thirty-three cases were included (median age 50 years,81.8% male). The patients with a single tumor had 23 cases (69.7%), and a total of 10 patients(30.3%) has two and more tumors. 21 cases (63.6%) were smaller than 10 cm of tumor diameter. The median of operation time was 200 minutes (110-360), Portal vein occlusion occurred in 12 patients(36.4%). Patients with intrahepatic recurrence received vertebroplasty combined chemotherapy(VPCC), targeted therapy , trans-arterial chemo-embolization(TACE) and radio frequency catheter ablation(RFCA) in 1(3%),1(3%),10(30.3%) and 7(12.1%) cases respectively. The 2- and 3- year cumulative probability of overall survival (OS) were 63% and 41%. The median OS was 30.8 months. The median recurrence time was 6 months(1.7-4.8). The median of confirmed PM time from HCC was 12.5 months(1.5-61.1) and 17(51.5%) patients died. Conclusion: Early detection of intrahepatic recurrence and treatment can prolong PM time and overall survival time.

Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment free remission (TFR) with generic imatinib. In a single center prospective Generic Imatinib Free Trial - in -CML-CP (GIFT-in-CML-CP) study, twenty-six patients on generic imatinib for more than 3 years and in sustained deep molecular response (BCR ABLIS <0.01% for more than 2 years) were included. After treatment discontinuation, patients were monitored with complete blood count and BCR ABLIS by real time quantitative PCR monthly for one year and three monthly thereafter. Generic imatinib was restarted at single documented loss of major molecular response. At a median follow-up of 20 months (range, 4-34 months), 42.3% patients (n=11) continued to be in TFR. Estimated TFR at 1 year was 44%. All patients restarted on generic imatinib regained major molecular response. On multivariate analysis, attainment of complete molecular remission (CMR) prior to TFR trial was predictive of TFR [p=0.022, HR 0.284 (0.096-0.837)]. We conclude that , generic imatinib can be safely discontinued in CML-CP patients who are in deep molecular remission.